research use only

Amphotericin B Antibiotics for Mammalian Cell Culture inhibitor

Cat.No.S1636

Amphotericin B (AMB, NSC 527017) is an amphipathic polyene antibiotic which permeabilizes ergosterol-containing membranes.
Jump to

Quality Control

Batch: Purity: 99.61%
99.61

Solubility

In vitro
Batch:

DMSO : 4.5 mg/mL (4.86 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 4.5 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 924.08 Formula

C47H73NO17

Storage (From the date of receipt)
CAS No. 1397-89-3 Download SDF Storage of Stock Solutions

Synonyms NSC 527017 SMILES CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
ergosterol
In vitro
Amphotericin B administration is limited by infusion-related toxicity, including fever and chills, an effect postulated to result from proinflammatory cytokine production by innate immune cells. This compound induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14. It interacts with cholesterol, the major sterol of mammal membranes, thus limiting the usefulness of this chemical due to its relatively high toxicity. This drug is dispersed as a pre-micellar or as a highly aggregated state in the subphase. It only kills unicellular Leishmania promastigotes (LPs) when aqueous pores permeable to small cations and anions are formed. This compound (0.1 mM) induces a polarization potential, indicating K+ leakage in KCl-loaded liposomes suspended in an iso-osmotic sucrose solution. It (0.05 mM) exhibits a nearly total collapse of the negative membrane potential, indicating Na+ entry into the cells.
In vivo
Amphotericin B results in prolonging the incubation time and decreasing PrPSc accumulation in the hamster scrapie model. This compound markedly reduces PrPSc levels in mice with transmissible subacute spongiform encephalopathies (TSSE). It exerts a direct effect on Plasmodium falciparum and influences eryptosis of infected erythrocytes, parasitemia and hostsurvival in murine malaria. This chemical tends to delay the increase of parasitemia and significantly delays host death plasmodium berghei-infected mice.
References
  • [4] https://pubmed.ncbi.nlm.nih.gov/7915757/
  • [5] https://pubmed.ncbi.nlm.nih.gov/12741794/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-07-27)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05814432 RECRUITING
Disseminated Histoplasma Capsulatum Infection; AIDS and Infections; Immunosuppression; Fungal Infection
Federal University of Health Science of Porto Alegre
2025-01-16 PHASE3
NCT06525389 NOT_YET_RECRUITING
Talaromycosis
Duke University
2026-09-01 PHASE3
NCT07463040 NOT_YET_RECRUITING
Cutaneous Leihmaniasis
Institute of Tropical Medicine, Belgium
2027-01-01 PHASE3
NCT07559032 NOT_YET_RECRUITING
Invasive Fungal Disease
Peking University People's Hospital
2026-04
NCT07725874 NOT_YET_RECRUITING
Invasive Mold Diseases
Beijing Friendship Hospital
2026-08-08
NCT07530263 NOT_YET_RECRUITING
Chronic Pulmonary Aspergillosis
Radboud University Medical Center
2026-10-01 PHASE1

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.